Clozapine is recommended by multiple international treatment guidelines, after resistance to two other antipsychotic medications and is the only treatment likely to result in improvement if two (or one[9]) other antipsychotic has not had a satisfactory effect.[10][11][12][13][14][15][16] Long term follow-up studies from Finland show significant improvements in terms of overall mortality including from suicide and all causes.[17] Clozapine is on the
World Health Organization's List of Essential Medicines.[18] It is available as a
generic medication and so it is not usually promoted by pharmaceutical companies.[19] Common adverse effects include
drowsiness,
constipation,
hypersalivation (increased saliva production),
tachycardia,
low blood pressure,
blurred vision, weight gain, and
dizziness.[19] Clozapine is not normally associated with
tardive dyskinesia (TD) and is recommended as the drug of choice when this is present, although some case reports describe clozapine-induced TD.[20] Potential adverse effects include
agranulocytosis,
seizures,
myocarditis (inflammation of the heart),
hyperglycemia (high blood glucose levels), and
constipation. The use of this drug can rarely result in clozapine-induced gastric hypomotility syndrome which may lead to
bowel obstruction and death, and in older people with psychosis, as a result of
dementia it may lead to an increased risk of death.[21][22] The mechanism of action is not entirely clear in the current medical literature.[19]
History
Clozapine was synthesized in 1958 by Wander AG, a Swiss pharmaceutical company, based on the chemical structure of the tricyclic antidepressant
imipramine.[23][24] The first test in humans in 1962 was considered a failure. Trials in Germany in 1965 and 1966 as well as a trial in Vienna in 1966 were successful. In 1967 Wander AG was acquired by
Sandoz.[23] Further trials took place in 1972 when clozapine was released in Switzerland and Austria as Leponex.[23] Two years later it was released in West Germany and in Finland in 1975.[23] Early testing was performed in the United States around the same time.[23] In 1975, 16 cases of
agranulocytosis leading to 8 deaths in clozapine-treated patients, reported from 6 hospitals mostly in southwestern Finland, led to concern.[25] Analysis of the Finnish cases revealed that all the agranulocytosis cases had occurred within the first 18 weeks of treatment and the authors proposed blood monitoring during this period.[26] The rate of agranulocytosis in Finland appeared to be 20 times higher than in the rest of the world and there was speculation that this may have been due a unique genetic variant in the region.[27][28][29] Whilst the drug continued to be manufactured by
Sandoz, and remained available in Europe, development in the U.S. halted.
Interest in clozapine continued in an investigational capacity in the United States because, even in the 1980s, the duration of hospitalisation, especially in
State Hospitals for those with treatment resistant schizophrenia might often be measured in years rather than days.[23] The role of clozapine in treatment resistant schizophrenia was established by the landmark Clozaril Collaborative Study Group Study #30 in which clozapine showed marked benefits compared to chlorpromazine in a group of patients with protracted psychosis and who had already shown an inadequate response to other antipsychotics. This involved both stringent blood monitoring and a double-blind design with the power to demonstrate superiority over standard antipsychotic treatment. The inclusion criteria were patients who had failed to respond to at least three previous antipsychotics and had then not responded to a single blind treatment with haloperidol (mean dose 61 mg +/− 14 mg/d). Two hundred and sixty-eight were randomised were to double blind trials of clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d). 30% of the clozapine patients responded compared to 4% of the controls, with significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas.[30] Following this study, the US
Food and Drug Administration (FDA) approved its use in 1990. Cautious of this risk, however, the FDA required a black box warning for specific side effects including agranulocytosis, and took the unique step of requiring patients to be registered in a formal system of tracking so that blood count levels could be evaluated on a systematic basis.[29][31]
In December 2002, clozapine was approved in the US for reducing the risk of suicide in people with schizophrenia or
schizoaffective judged to be at chronic risk for suicidal behavior.[32] In 2005, the FDA approved criteria to allow reduced blood monitoring frequency.[33] In 2015, the individual manufacturer Patient Registries were consolidated by request of the FDA into a single shared Patient Registry Called The Clozapine REMS Registry.[34] Despite the demonstrated safety of the new FDA monitoring requirements, which have lower neutrophil levels and do not include total white cell counts, international monitoring has not been standardised.[35][36][37]
Chemistry
Clozapine is a
dibenzodiazepine that is structurally very similar to
loxapine (originally deemed a typical antipsychotic). It is slightly soluble in water, soluble in
acetone, and highly soluble in
chloroform. Its solubility in water is 0.1889 mg/L (25 °C).[5] Its manufacturer, Novartis, claims a solubility of <0.01% in water (<100 mg/L).[38]
Clinical uses
Schizophrenia
The role of clozapine in treatment-resistant schizophrenia was established by a 1988 landmark multicenter double blind study[39] in which clozapine (up to 900 mg/d) showed marked benefits compared to
chlorpromazine (up to 1800 mg/d) in a group of patients with protracted psychosis who had already shown an inadequate response to at least three previous antipsychotics including a prior single blind trial of haloperidol (mean 61+/− 14 mg/d for six weeks).[30] While there are significant side effects, clozapine remains the most effective treatment when one or more other antipsychotics have had an inadequate response. The use of clozapine is associated with multiple improved outcomes, including a reduced rate of all-cause mortality, suicide and hospitalization.[17][40][41] In a 2013 network comparative meta-analysis of 15 antipsychotic drugs, clozapine was found to be significantly more effective than all other drugs.[42] In a 2021 UK study, the majority of patients (over 85% of respondents) who took clozapine preferred it to their previous therapies, felt better on it and wanted to keep taking it.[43] In a 2000 Canadian survey of 130 patients, the majority reported better satisfaction, quality of life, compliance with treatment, thinking, mood, and alertness.[44][unreliable medical source?]
Clozapine is usually used for people diagnosed with
schizophrenia who have had an inadequate response to other antipsychotics or who have been unable to tolerate other drugs due to extrapyramidal side effects. It is also used for the treatment of psychosis in
Parkinson's Disease.[7][8] It is regarded as the
gold-standard treatment when other medication has been insufficiently effective and its use is recommended by multiple international treatment guidelines, supported by
systematic reviews and
meta-analysis.[10][11][12][13][14][15][45][46] Whilst all current guidelines reserve clozapine for individuals in whom two other antipsychotics have already been tried, evidence indicates that clozapine might instead be used as a second line drug.[9] Clozapine treatment has been demonstrated to produce improved outcomes in multiple domains including; a reduced risk of hospitalisation, a reduced risk of drug discontinuation, a reduction in overall symptoms and has improved efficacy in the treatment of positive psychotic symptoms of schizophrenia.[40][41][47][48] Despite a range of side effects patients report good levels of satisfaction and long term adherence is favourable compared to other antipsychotics.[49] Very long term follow-up studies reveal multiple benefits in terms of reduced mortality,[17][50] with a particularly strong effect for reduced death by suicide, clozapine is the only antipsychotic known to have an effect reducing the risk of suicide or attempted suicide.[51] Clozapine has a significant anti-aggressive effect.[52][53][54][55][56] Clozapine is widely used in secure and forensic mental health settings where improvements in aggression, shortened admission and reductions in restrictive practice such as seclusion have been found.[57][58][59][60][61][62][63][64][65] In secure hospitals and other settings clozapine has also been used in the treatment of borderline and antisocial personality disorder when this has been associated with violence or self-harm.[66][67][52] Although oral treatment is almost universal clozapine has on occasion been enforced using either nasogastric or a short acting injection although in almost 50% of the approximately 100 reported cases patients agreed to take oral medication prior to the use of a coercive intervention.[58][68][60][69][70][71][62][72][61][73] Clozapine has also been used off-label to treat catatonia with success in over 80% of cases.[74]
Bipolar disorder
On the basis of systematic reviews clozapine is recommended in some treatment guidelines as a third or fourth line treatment for
bipolar disorder.[75][76][77][78] A long term follow-uo study showed efficacy in terms of both psychiatric and somatic hospitialisation, but with bipolar disorder this effect was not as strong as with some other treatments (olanzapine long-acting injection (LAI) (aHR = 0.54, 95% CI 0.37–0.80), haloperidol LAI (aHR = 0.62, 0.47–0.81), zuclopenthixol LAI (aHR = 0.66, 95% CI 0.52–0.85), lithium (aHR = 0.74, 95% CI 0.71–0.76) and clozapine (aHR = 0.75, 95% CI 0.64–0.87)).[79] Bipolar disorder is an off-label indication for clozapine.[citation needed]
Whilst clozapine is usually initiated in hospital setting community initiation is also available.[87][88] Before clozapine can be initiated multiple assessments and baseline investigations are performed. In the UK and Ireland there must be an assessment that the patient satisfies the criteria for prescription; treatment resistant schizophrenia, intolerance due to extrapyramidal symptoms of other antipsychotics or psychosis in Parkinson's disease. Establishing a history of treatment resistance may include careful review of the medication history including the durations, doses and compliance of previous antipsychotic therapy and that these did not have an adequate clinical effect. A diagnostic review may also be performed. That could include review of antipsychotic plasma concentrations if available. The prescriber, patient, pharmacy and the laboratory performing blood counts are all registered with a specified clozapine provider who must be advised that there is no history of neutropenia from any cause. The clozapine providers collaborate by sharing information regarding patients who have had clozapine related neutropenia or agranulocytosis so that clozapine cannot be used again on license. Clozapine may only be dispensed after a satisfactory blood result has been received by the risk monitoring agency at which point an individual prescription may be released to an individual patient only.[89]
Baseline tests usually also include; a physical examination including baseline weight,
waist circumference and
BMI, assessments of
renal function and
liver function, an
ECG and other baseline bloods may also be taken to facilitate monitoring of possible myocarditis, these might include
C reactive protein (CRP) and
troponin. In Australia and New Zealand pre-clozapine
echocardiograms are also commonly performed.[90] A number of service protocols are available and there are variations in the extent of pre-clozapine work ups. Some might also include
fasting lipids,
HbA1c and
prolactin. At the
Maudsley Hospital in the UK the Treat service also routinely performs a wide variety of other investigations including multiple investigations for other causes of psychosis and comorbidities including;
MRI brain imaging,
thyroid function tests,
B12,
folate and
serum calcium levels, infection screening for blood borne viruses including
Hepatitis B and C,
HIV and
syphilis as well as screening for autoimmune psychosis by
anti-NMDA,
anti-VGKC and
Anti-nuclear Antibody screening. Investigations used to monitor the possibility of clozapine related side effects such as myocarditis are also performed including baseline troponin, CRP and
BNP and for
neuroleptic malignant syndromeCK.[88]
The dose of clozapine is initially low and gradually increased over a number of weeks. Initial doses may range from 6.5 to 12.5 mg/d increasing stepwise typically to doses in the range of 250–350 mg per day at which point an assessment of response will be performed.[90] In the UK the average clozapine dose is 450 mg/d.[91][92] But response is highly variable and some patients respond at much lower doses and vice versa.
Monitoring
During the initial dose titration phase the following are typically monitored, usually daily at first: pulse, blood pressure, and temperature. Since
orthostatic hypotension can be problematic, blood pressure should be monitored both sitting and standing. If there is a significant drop then the rate of the dose increase may be slowed.[88]
Mandatory full blood counts are performed weekly for the first 18 weeks. In some services there will also be monitoring of markers that might indicate myocarditis, troponin, CRP and BNP, although the exact tests and frequency vary between services. Weight is usually measured weekly.
Thereon other investigations and monitoring will always include full blood counts (fortnightly for 1 year then monthly). Weight, waist circumference, lipids and glucose or HbA1c may also be monitored.
Clozapine response and treatment optimisation
As with other antipsychotics, and in contrast to received wisdom, responses to clozapine are typically seen soon after initiation and often within the first week.[93][94] That said responses, especially those which are partial, can be delayed.[95] Quite what an adequate trial of clozapine is, is uncertain but a recommendation is that this should be for at least 8 weeks on a plasma trough level above 350-400 micro g/L.[96][97] There is considerable inter-individual variation. A significant number of patients respond at lower and also much higher plasma concentrations and some patients, especially young male smokers may never achieve these plasma levels even at doses of 900 mg/day. Options then include either increasing the dose above the licensed maximum or the addition of a drug that inhibits clozapine metabolism. Avoiding unnecessary
polypharmacy is a general principle in drug treatment.
Optimising blood sampling
The neutrophil cut off for clozapine have shown an exceptional ability to mitigate the risk of neutropenia and agranulocytosis. There is a significant margin of safety. Some patients may have marginal neutrophil counts before and after initiation and they are at risk of premature clozapine discontinuation. A knowledge of neutrophil biology allows blood sampling optimisation. Neutrophils show a diurnal variation in response to the natural cycle of G-CSF production, they are increased in the afternoons, they are also mobilised into the circulation after exercise and smoking. Simply shifting blood sampling has been shown to avoid unnecessary discontinuations, especially in black populations. However this is a disruption to usual hospital practice. Other practical steps are to ensure that blood results become available in hours and when senior staff are available.[59]
Psychiatrists' prescribing practices have been found to be the most significant variable regarding variance in its use.[citation needed] Surveys of psychiatrists' attitudes to clozapine have found that many had little experience in its use, overestimated the incidence of side effects, and did not appreciate that many patients prefer to take clozapine over other antipsychotics.[111][112][113] In contrast to many psychiatrists' expectations most patients believe that the blood testing and other difficulties are worth the multiple benefits that they perceive.[43][44] Whilst psychiatrists fear the severe adverse effects such as
agranulocytosis, patients are more concerned about hypersalivation.[114] Clozapine is no longer actively marketed and this may also be one of the explanations for its underuse.[115]
Despite the strong evidence and universal endorsement by national and international treatment guidelines and the experiences of patients themselves, most people eligible for clozapine are not treated with it.[43] A large study in England found that approximately 30% of those eligible for clozapine were being treated with it.[116] Those patients that do start clozapine usually face prolonged delay, multiple episodes of psychosis and treatments such as high dose antipsychotics or polypharmacy. Instead of two previous antipsychotics many will have been exposed to ten or more drugs which were not effective. A study of 120 patients conducted in four hospitals in South-East London found a mean of 9.2 episodes of antipsychotic prescription before clozapine was initiated and the mean delay in using clozapine was 5 years.[117] Treatments that have no evidence base or are regarded as actively harmful are used instead.[118]
Racial disparity in the use of clozapine
A general finding in healthcare provision is that minority groups receive inferior treatment; this is a particular finding in the US.[119][120][121][122] In the US a general finding is that compared to their white peers African American people are less likely to be prescribed the second generation antipsychotics, which are more expensive than alternatives and this was even apparent and especially so for clozapine when comparison was made in the
Veterans Affairs medical system and when differences regarding socioeconomic factors were taken into account.[107][108][123] As well as being less likely to start clozapine black patients are more likely to stop clozapine, possibly on account of
benign ethnic neutropenia.
Benign ethnic neutropenia
Benign reductions in neutrophils are observed in individuals of all ethnic backgrounds ethnic neutropenia (BEN), neutropenia without immune dysfunction or increased liability to infection is not due to abnormal neutrophil production; although, the exact aetiology of the reduction in circulating cells remains unknown. BEN is associated with several ethnic groups, but in particular those with Black African and West African ancestry.[124] A difficulty with the use of clozapine is that neutrophil counts have been standardised on white populations.[125] For significant numbers of black patients the standard neutrophil count thresholds did not permit clozapine use as the thresholds did not take BEN into account. Since 2002, clozapine monitoring services in the UK have used reference ranges 0.5 × 109/l lower for patients with haematologically confirmed BEN and similar adjustments are available in the current US criteria, although with lower permissible minima.[64][36][126] But even then significant numbers of black patients will not be eligible even though the low neutrophil counts do not in their case reflect disease. The
Duffy–Null polymorphism, which protects against some types of malaria, is predictive of BEN.[127]
Adverse effects
Clozapine may cause serious and potentially fatal adverse effects. Clozapine carries five
black box warnings, including (1) severe
neutropenia (low levels of neutrophils), (2)
orthostatic hypotension (low blood pressure upon changing positions), including
slow heart rate and
fainting, (3) seizures, (4)
myocarditis (inflammation of the heart), and (5) risk of death when used in elderly people with dementia-related psychosis.[4] Lowering of the
seizure threshold may be dose related. Increasing the dose slowly may decrease the risk for seizures and orthostatic hypotension.[128]
Common effects include
constipation, bed-wetting, night-time
drooling,
muscle stiffness,
sedation,
tremors, orthostatic hypotension, high blood sugar, and
weight gain. The risk of developing
extrapyramidal symptoms, such as
tardive dyskinesia, is below that of typical antipsychotics; this may be due to clozapine's anticholinergic effects. Extrapyramidal symptoms may subside somewhat after a person switches from another antipsychotic to clozapine.[128] Sexual problems, such as
retrograde ejaculation, have been reported while taking clozapine.[4] Rare adverse effects include periorbital edema.[129] Despite the risk for numerous side effects, many side effects can be managed while continuing to take clozapine.[130]
Compared to other antipsychotics, clozapine has an increased risk of
blood dyscrasias, in particular
agranulocytosis, in the first 18 weeks of treatment. After one year, this risk reduces to that associated with most antipsychotics. Clozapine's use is therefore usually reserved for people who have not responded to at least two other antipsychotics and is only done with stringent blood monitoring.[7] Overall, despite the concerns relating to blood and other side effects, clozapine use is associated with a reduced mortality, especially from suicide which is a major cause of premature death in people with schizophrenia.[131] The risk of clozapine related agranulocytosis and neutropenia warranted the mandatory use of stringent risk monitoring and management systems, which have reduced the risk of death from these adverse events to around 1 in 7,700.[132] The association between clozapine use and specific blood dyscrasias was first noted in the 1970s when eight deaths from agranulocytosis were noted in Finland.[27] At the time it was not clear if this exceeded the established rate of this side effect which is also found in other antipsychotics and although the drug was not completely withdrawn, its use became limited.[23]
Clozapine Induced
Neutropenia (CIN) occurs in approximately 3.8% of cases and Clozapine Induced
Agranulocytosis (CIA) in 0.4%.[133] These are potentially serious side effects and agranulocytosis can result in death. To mitigate this risk clozapine is only used with mandatory
absolute neutrophil count (ANC) monitoring (neutrophils are the most abundant of the granulocytes); for example, in the United States, the Risk Evaluation and Mitigation Strategy (REMS).[134] The exact schedules and blood count thresholds vary internationally[36] and the thresholds at which clozapine can be used in the U.S. has been lower than those currently used in the U.K. and Australasia for some time.[135] The effectiveness of the risk management strategies used is such that deaths from these side effects are very rare occurring at approximately 1 in 7700 patients treated.[132] Almost all the adverse blood reactions occur within the first year of treatment and the majority within the first 18 weeks.[133] After one year of treatment these risks reduce markedly to that seen in other antipsychotic drugs 0.01% or about 1 in 10,000 and the risk of death is markedly lower still.[132] When reductions in neutrophil levels are noted on regular blood monitoring then, depending on the value, monitoring may be increased or, if the neutrophil count is sufficiently low, then clozapine is stopped immediately and can then no longer be used within the medicinal licence. Stopping clozapine almost always results in resolution of the neutrophil reduction.[133][132] However severe agranulocytosis can result in spontaneous infection and death, is a severe decrease in the amount of a specific kind of
white blood cell called
granulocytes. Clozapine carries a
black box warning for drug-induced agranulocytosis. Rapid
point-of-care tests may simplify the monitoring for agranulocytosis.[136]
Clozapine rechallenge
A clozapine "rechallenge" is when someone that experienced agranulocytosis while taking clozapine starts taking the medication again. In countries in which the neutrophil thresholds are higher than those used in the US a simple approach is, if the lowest ANC had been above the US cut off, to reintroduce clozapine but with the US monitoring regime. This has been demonstrated in a large cohort of patients in a hospital in London in which it was found that of 115 patients who had had clozapine stopped according to the US criteria only 7 would have had clozapine stopped if the US cut offs had been used. Of these 62 were rechallenged, 59 continued to use clozapine without difficulty and only 1 had a fall in neutrophils below the US cut off.[37] Other approaches have included the use of other drugs to support neutrophil counts including
lithium or
granulocyte colony-stimulating factor (G-CSF). However, if agranulocytosis still occurs during a rechallenge, the alternative options are limited.[137][138]
Cardiac toxicity
Clozapine can rarely cause
myocarditis and
cardiomyopathy. A large meta-analysis of clozapine exposure to over 250,000 people revealed that these occurred in approximately 7 in 1000 patients treated and resulted in death in 3 and 4 in 10,000 patients exposed respectively and although myocarditis occurred almost exclusively within the first 8 weeks of treatment, cardiomyopathy can occur much later on.[139] First manifestations of illness are fever which may be accompanied by symptoms associated with upper respiratory tract, gastrointestinal or urinary tract infection. Typically
C-reactive protein (CRP) increases with the onset of fever and rises in the cardiac enzyme,
troponin, occur up to 5 days later. Monitoring guidelines advise checking CRP and troponin at baseline and weekly for the first 4 weeks after clozapine initiation and observing the patient for signs and symptoms of illness.[140] Signs of
heart failure are less common and may develop with the rise in troponin. A recent case-control study found that the risk of clozapine-induced myocarditis is increased with increasing rate of clozapine dose titration, increasing age and concomitant sodium valproate.[141] A large electronic health register study has revealed that nearly 90% of cases of suspected clozapine related myocarditis are false positives.[142] Rechallenge after clozapine induced myocarditis has been performed and a protocol for this specialist approach has been published.[143] A systematic review of rechallenge after myocarditis has shown success in over 60% of reported cases.[144]
Gastrointestinal hypomotility
Another underrecognized and potentially life-threatening effect spectrum is gastrointestinal hypomotility, which may manifest as severe
constipation,
fecal impaction, paralytic
ileus,
bowel obstruction, acute megacolon,
ischemia or
necrosis.[145] Colonic hypomotility has been shown to occur in up to 80% of people prescribed clozapine when
gastrointestinal function is measured objectively using
radiopaque markers.[146] Clozapine-induced gastrointestinal hypomotility currently has a higher mortality rate than the better known side effect of agranulocytosis.[147] A
Cochrane review found little evidence to help guide decisions about the best treatment for gastrointestinal hypomotility caused by clozapine and other
antipsychotic medication.[148] Monitoring bowel function and the preemptive use of
laxatives for all clozapine-treated people has been shown to improve colonic transit times and reduce serious sequelae.[149]
Hypersalivation
Hypersalivation, or the excessive production of saliva, is one of the most common adverse effects of clozapine (30–80%).[150] The saliva production is especially bothersome at night and first thing in the morning, as the immobility of sleep precludes the normal clearance of saliva by swallowing that occurs throughout the day.[150] While clozapine is a
muscarinic antagonist at the
M1,
M2,
M3, and
M5 receptors, clozapine is a full agonist at the
M4 subset. Because M4 is highly expressed in the
salivary gland, its M4 agonist activity is thought to be responsible for hypersalivation.[151] clozapine-induced hypersalivation is likely a dose-related phenomenon, and tends to be worse when first starting the medication.[150] Besides decreasing the dose or slowing the initial dose titration, other interventions that have shown some benefit include systemically absorbed anticholinergic medications such as
hyoscine,[152]diphenhydramine[150] and topical anticholinergic medications like
ipratropium bromide.[153] Mild hypersalivation may be managed by sleeping with a towel over the pillow at night.[153]
Abrupt withdrawal may lead to
cholinergicrebound effects, such as indigestion, diarrhea, nausea/vomiting, overabundance of saliva, profuse sweating, insomnia, and agitation.[158] Abrupt withdrawal can also cause severe movement disorders, catatonia, and psychosis.[159] Doctors have recommended that patients, families, and caregivers be made aware of the symptoms and risks of abrupt withdrawal of clozapine. When discontinuing clozapine, gradual dose reduction is recommended to reduce the intensity of withdrawal effects.[160][161]
Weight gain and diabetes
In addition to
hyperglycemia, significant
weight gain is frequently experienced by patients treated with clozapine.[162] Impaired glucose metabolism and
obesity have been shown to be constituents of the
metabolic syndrome and may increase the risk of
cardiovascular disease. The data suggest that clozapine may be more likely to cause adverse metabolic effects than some of the other
atypical antipsychotics.[163] For people who gain weight because of clozapine, taking
metformin may reportedly improve three of the five components of the metabolic syndrome: waist circumference, fasting glucose, and fasting triglycerides.[164]
Pneumonia
International adverse drug effect databases indicate that clozapine use is associated with a significantly increased incidence of and death from pneumonia and this may be one of the most significant adverse events.[165] The mechanisms for this are unknown although it has been speculated that it may be related to hypersalivation or the immune effects of clozapine's effects on the resolution of inflammation.[166][167]
Overdose
This section needs expansion. You can help by
adding to it. (August 2019)
Symptoms of overdose can be variable, but often include;
sedation,
confusion,
tachycardia,
seizures and
ataxia. Fatalities have been reported due to clozapine overdose, though overdoses of greater than 5000 mg have been survived.[168][169]
Drug interactions
Fluvoxamine inhibits the metabolism of clozapine leading to significantly increased blood levels of clozapine.[170]
When
carbamazepine is concurrently used with clozapine, it has been shown to decrease plasma levels of clozapine significantly thereby decreasing the beneficial effects of clozapine.[171][172] Patients should be monitored for "decreased therapeutic effects of clozapine if carbamazepine" is started or increased. If carbamazepine is discontinued or the dose of
carbamazepine is decreased, therapeutic effects of clozapine should be monitored. The study recommends
carbamazepine to not be used concurrently with clozapine due to increased risk of
agranulocytosis.[173]
Ciprofloxacin is an inhibitor of
CYP1A2 and clozapine is a major CYP1A2 substrate. Randomized study reported elevation in clozapine concentration in subjects concurrently taking
ciprofloxacin.[174] Thus, the prescribing information for clozapine recommends "reducing the dose of clozapine by one-third of original dose" when
ciprofloxacin and other
CYP1A2 inhibitors are added to therapy, but once
ciprofloxacin is removed from therapy, it is recommended to return clozapine to original dose.[175]
Clozapine is an antagonist at the 5-HT2A subtype of the serotonin receptor, putatively improving depression, anxiety, and the negative cognitive symptoms associated with schizophrenia.[179][180]
A direct interaction of clozapine with the
GABAB receptor has also been shown.[181] GABAB receptor-deficient mice exhibit increased extracellular dopamine levels and altered
locomotor behaviour equivalent to that in schizophrenia animal models.[182] GABAB receptor agonists and
positive allosteric modulators reduce the locomotor changes in these models.[183]
The absorption of clozapine is almost complete following oral administration, but the oral
bioavailability is only 60 to 70% due to
first-pass metabolism. The time to peak concentration after oral dosing is about 2.5 hours, and food does not appear to affect the bioavailability of clozapine. However, it was shown that co-administration of food decreases the rate of absorption.[186] The
elimination half-life of clozapine is about 14 hours at
steady state conditions (varying with daily dose).[medical citation needed]
Clozapine is extensively metabolized in the liver, via the
cytochrome P450 system, to
polar metabolites suitable for elimination in the urine and feces. The major metabolite, norclozapine (
desmethyl-clozapine), is pharmacologically active. The cytochrome P450
isoenzyme1A2 is primarily responsible for clozapine metabolism, but 2C,
2D6,
2E1 and
3A3/4 appear to play roles as well. Agents that
induce (e.g., cigarette smoke) or
inhibit (e.g.,
theophylline,
ciprofloxacin,
fluvoxamine) CYP1A2 may increase or decrease, respectively, the metabolism of clozapine. For example, the induction of metabolism caused by smoking means that smokers require up to double the dose of clozapine compared with non-smokers to achieve an equivalent plasma concentration.[187]
Clozapine and norclozapine (desmethyl-clozapine) plasma levels may also be monitored, though they show a significant degree of variation and are higher in women and increase with age.[188] Monitoring of plasma levels of clozapine and norclozapine has been shown to be useful in assessment of compliance, metabolic status, prevention of toxicity, and in dose optimisation.[187]
Despite the expense of the risk monitoring and management systems required, clozapine use is highly cost effective; with a number of studies suggesting savings of tens of thousands of dollars per patient per year compared to other antipsychotics as well as advantages regarding improvements in quality of life.[189][190][191] Clozapine is available as a
generic medication.[19]
^
abHopfinger AJ, Esposito EX, Llinàs A, Glen RC, Goodman JM (January 2009). "Findings of the challenge to predict aqueous solubility". Journal of Chemical Information and Modeling. 49 (1): 1–5.
doi:
10.1021/ci800436c.
PMID19117422.
^
abNational Institute for Health and Care Excellence (Great Britain). Parkinson's disease in adults : diagnosis and management : full guideline.
OCLC1105250833.
^
abHasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. (July 2012). "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance". The World Journal of Biological Psychiatry. 13 (5): 318–378.
doi:
10.3109/15622975.2012.696143.
PMID22834451.
S2CID20370225.
^World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization.
hdl:
10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^
abcd"Clozapine". The American Society of Health-System Pharmacists.
Archived from the original on 8 December 2015. Retrieved 1 December 2015.
^Pardis P, Remington G, Panda R, Lemez M, Agid O (October 2019). "Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review". Journal of Psychopharmacology. 33 (10): 1187–1198.
doi:
10.1177/0269881119862535.
PMID31347436.
S2CID198912192.
^Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P (October 1977). "Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic". Acta Psychiatrica Scandinavica. 56 (4): 241–248.
doi:
10.1111/j.1600-0447.1977.tb00224.x.
PMID920225.
S2CID24782844.
^
abde With SA, Pulit SL, Staal WG, Kahn RS, Ophoff RA (July 2017). "More than 25 years of genetic studies of clozapine-induced agranulocytosis". The Pharmacogenomics Journal. 17 (4): 304–311.
doi:
10.1038/tpj.2017.6.
PMID28418011.
S2CID5007914.
^
abKane J, Honigfeld G, Singer J, Meltzer H (September 1988). "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine". Archives of General Psychiatry. 45 (9): 789–796.
doi:
10.1001/archpsyc.1988.01800330013001.
PMID3046553.
^Nyakyoma K, Morriss R (2010). "Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study". Psychopharmacology Bulletin. 43 (2): 67–81.
PMID21052043.
^Dalal B, Larkin E, Leese M, Taylor PJ (June 1999). "Clozapine treatment of long-standing schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital". Criminal Behaviour and Mental Health. 9 (2): 168–178.
doi:
10.1002/cbm.304.
^Topiwala A, Fazel S (January 2011). "The pharmacological management of violence in schizophrenia: a structured review". Expert Review of Neurotherapeutics. 11 (1): 53–63.
doi:
10.1586/ern.10.180.
PMID21158555.
S2CID2190383.
^
abFisher WA (January 2003). "Elements of successful restraint and seclusion reduction programs and their application in a large, urban, state psychiatric hospital". Journal of Psychiatric Practice. 9 (1): 7–15.
doi:
10.1097/00131746-200301000-00003.
PMID15985912.
S2CID2926142.
^Swinton M, Haddock A (January 2000). "Clozapine in Special Hospital: a retrospective case-control study". The Journal of Forensic Psychiatry. 11 (3): 587–596.
doi:
10.1080/09585180010006205.
ISSN0958-5184.
S2CID58172685.
^
abHaw C, Stubbs J (November 2011). "Medication for borderline personality disorder: a survey at a secure hospital". International Journal of Psychiatry in Clinical Practice. 15 (4): 280–285.
doi:
10.3109/13651501.2011.590211.
PMID22122000.
S2CID43305.
^Lokshin P, Lerner V, Miodownik C, Dobrusin M, Belmaker RH (October 1999). "Parenteral clozapine: five years of experience". Journal of Clinical Psychopharmacology. 19 (5): 479–480.
doi:
10.1097/00004714-199910000-00018.
PMID10505595.
^Schulte PF, Stienen JJ, Bogers J, Cohen D, van Dijk D, Lionarons WH, et al. (November 2007). "Compulsory treatment with clozapine: a retrospective long-term cohort study". International Journal of Law and Psychiatry. 30 (6): 539–545.
doi:
10.1016/j.ijlp.2007.09.003.
PMID17928054.
^Mossman D, Lehrer DS (December 2000). "Conventional and atypical antipsychotics and the evolving standard of care". Psychiatric Services. 51 (12): 1528–1535.
doi:
10.1176/appi.ps.51.12.1528.
PMID11097649.
^Goodwin GM (June 2009). "Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 23 (4): 346–388.
doi:
10.1177/0269881109102919.
PMID19329543.
S2CID27827654.
^Beri A, Boydell J (May 2014). "Clozapine in borderline personality disorder: a review of the evidence". Annals of Clinical Psychiatry. 26 (2): 139–144.
PMID24812651.
^Frogley C, Anagnostakis K, Mitchell S, Mason F, Taylor D, Dickens G, et al. (May 2013). "A case series of clozapine for borderline personality disorder". Annals of Clinical Psychiatry. 25 (2): 125–134.
PMID23638443.
^
abTaylor D, Barnes TR, Young AH (2019). The Maudsley prescribing guidelines in psychiatry (13th ed.). Hoboken, NJ: Wiley.
ISBN978-1-119-44260-8.
OCLC1029071684.
^Taylor Shubhra Mace Shameem Mir Robert Kerwin D (January 2000). "A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom". International Journal of Psychiatry in Clinical Practice. 4 (1): 41–46.
doi:
10.1080/13651500052048749.
PMID24927311.
S2CID25337120.
^Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B (May 2005). "Evidence for onset of antipsychotic effects within the first 24 hours of treatment". The American Journal of Psychiatry. 162 (5): 939–946.
doi:
10.1176/appi.ajp.162.5.939.
PMID15863796.
^Remington G (2010). "Augmenting Clozapine Response in Treatment-Resistant Schizophreni a". Therapy-Resistant Schizophrenia. Advances in Biological Psychiatry. Vol. 26. Basel: KARGER. pp. 129–151.
doi:
10.1159/000319813.
ISBN978-3-8055-9511-7.
^Schulte P (2003). "What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia". Clinical Pharmacokinetics. 42 (7): 607–618.
doi:
10.2165/00003088-200342070-00001.
PMID12844323.
S2CID25525638.
^Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M (February 2014). "Geographic and clinical variation in clozapine use in the United States". Psychiatric Services. 65 (2): 186–192.
doi:
10.1176/appi.ps.201300180.
PMID24233347.
^Nielsen J, Røge R, Schjerning O, Sørensen HJ, Taylor D (November 2012). "Geographical and temporal variations in clozapine prescription for schizophrenia". European Neuropsychopharmacology. 22 (11): 818–824.
doi:
10.1016/j.euroneuro.2012.03.003.
PMID22503785.
S2CID40842497.
^Latimer E, Wynant W, Clark R, Malla A, Moodie E, Tamblyn R, et al. (April 2013). "Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec". Clinical Schizophrenia & Related Psychoses. 7 (1): 33–41.
doi:
10.3371/csrp.lawy.012513.
PMID23367500.
^
abMallinger JB, Fisher SG, Brown T, Lamberti JS (January 2006). "Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia". Psychiatric Services. 57 (1): 133–136.
doi:
10.1176/appi.ps.57.1.133.
PMID16399976.
^
abCopeland LA, Zeber JE, Valenstein M, Blow FC (October 2003). "Racial disparity in the use of atypical antipsychotic medications among veterans". The American Journal of Psychiatry. 160 (10): 1817–1822.
doi:
10.1176/appi.ajp.160.10.1817.
PMID14514496.
^Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, et al. (September 2006). "Clozapine utilization and outcomes by race in a public mental health system: 1994-2000". The Journal of Clinical Psychiatry. 67 (9): 1404–1411.
doi:
10.4088/jcp.v67n0911.
PMID17017827.
^Whiskey E, Olofinjana O, Taylor D (June 2011). "The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study". Journal of Psychopharmacology. 25 (6): 842–845.
doi:
10.1177/0269881110364267.
PMID20305043.
S2CID28714732.
^Nielsen J, Dahm M, Lublin H, Taylor D (July 2010). "Psychiatrists' attitude towards and knowledge of clozapine treatment". Journal of Psychopharmacology. 24 (7): 965–971.
doi:
10.1177/0269881108100320.
PMID19164499.
S2CID34614417.
^Hodge K, Jespersen S (February 2008). "Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians". International Journal of Mental Health Nursing. 17 (1): 2–8.
doi:
10.1111/j.1447-0349.2007.00506.x.
PMID18211398.
^Taylor DM, Young C, Paton C (January 2003). "Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review". The Journal of Clinical Psychiatry. 64 (1): 30–34.
doi:
10.4088/jcp.v64n0107.
PMID12590620.
^Fayek M, Flowers C, Signorelli D, Simpson G (November 2003). "Psychopharmacology: underuse of evidence-based treatments in psychiatry". Psychiatric Services. 54 (11): 1453–4, 1456.
doi:
10.1176/appi.ps.54.11.1453.
PMID14600298.
^Bulatao RA, Anderson NB, et al. (National Research Council (US) Panel on Race, Ethnicity, and Health in Later Life) (2004).
Stress. National Academies Press (US).
^Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, et al. (September 2006). "Clozapine utilization and outcomes by race in a public mental health system: 1994-2000". The Journal of Clinical Psychiatry. 67 (9): 1404–1411.
doi:
10.4088/JCP.v67n0911.
PMID17017827.
^Haddy TB, Rana SR, Castro O (January 1999). "Benign ethnic neutropenia: what is a normal absolute neutrophil count?". The Journal of Laboratory and Clinical Medicine. 133 (1): 15–22.
doi:
10.1053/lc.1999.v133.a94931.
PMID10385477.
^
ab"Clozapine". Pharmacology: MCQs.
Archived from the original on 10 November 2013 – via Google Sites.
^Teodoro T, Nogueira V, Aldeias J, Teles Martins M, Salgado J (September 2022). "Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia". Journal of Clinical Psychopharmacology. 42 (6): 594–596.
doi:
10.1097/JCP.0000000000001600.
PMID36066404.
S2CID252088054.
^
abcdLi XH, Zhong XM, Lu L, Zheng W, Wang SB, Rao WW, et al. (March 2020). "The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies". Psychological Medicine. 50 (4): 583–594.
doi:
10.1017/S0033291719000369.
PMID30857568.
S2CID75137940.
^
abcMyles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. (August 2018). "Meta-analysis examining the epidemiology of clozapine-associated neutropenia". Acta Psychiatrica Scandinavica. 138 (2): 101–109.
doi:
10.1111/acps.12898.
PMID29786829.
S2CID29157011.
^Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, et al. (May 2020). "Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy". The Australian and New Zealand Journal of Psychiatry. 54 (5): 467–481.
doi:
10.1177/0004867419898760.
PMID31957459.
S2CID210831575.
^Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ (June 2011). "A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls". The Australian and New Zealand Journal of Psychiatry. 45 (6): 458–465.
doi:
10.3109/00048674.2011.572852.
PMID21524186.
S2CID26627093.
^Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ (November 2012). "Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study". Schizophrenia Research. 141 (2–3): 173–178.
doi:
10.1016/j.schres.2012.08.018.
PMID23010488.
S2CID25720157.
^Griffin JM, Woznica E, Gilotra NA, Nucifora FC (March 2021). "Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge". Journal of Clinical Psychopharmacology. 41 (2): 180–185.
doi:
10.1097/JCP.0000000000001358.
PMID33587399.
S2CID231926010.
^Richardson N, Greenway SC, Bousman CA (November 2021). "Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review". Psychiatry Research. 305: 114247.
doi:
10.1101/2021.09.03.21263094.
PMID34715441.
S2CID237461869.
^Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M (May 2008). "Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases". The Journal of Clinical Psychiatry. 69 (5): 759–768.
doi:
10.4088/JCP.v69n0509.
PMID18452342.
^Every-Palmer S, Ellis PM, Nowitz M, Stanley J, Grant E, Huthwaite M, et al. (January 2017). "The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study". CNS Drugs. 31 (1): 75–85.
doi:
10.1007/s40263-016-0391-y.
PMID27826741.
S2CID46825178.
^Dadlani N, Austin M. Bethanechol and Aripiprazole for the management of refractory urinary incontinence in a patient on Clozapine. Aust N Z J Psychiatry. 2016 Feb;50(2):182. doi: 10.1177/0004867415583878. Epub 2015 Apr 28. PMID 25922356.
^Keck PE, McElroy SL (2002). "Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications". The Journal of Clinical Psychiatry. 63 (Suppl 4): 3–11.
PMID11913673.
^Broich K, Heinrich S, Marneros A (July 1998). "Acute clozapine overdose: plasma concentration and outcome". Pharmacopsychiatry. 31 (4): 149–151.
doi:
10.1055/s-2007-979318.
PMID9754851.
S2CID28623410.
^Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (December 1997). "Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence". Clinical Pharmacokinetics. 33 (6): 454–471.
doi:
10.2165/00003088-199733060-00004.
PMID9435993.
S2CID36883635.
^Tiihonen J, Vartiainen H, Hakola P (January 1995). "Carbamazepine-induced changes in plasma levels of neuroleptics". Pharmacopsychiatry. 28 (1): 26–28.
doi:
10.1055/s-2007-979584.
PMID7746842.
S2CID260249900.
^Jerling M, Lindström L, Bondesson U, Bertilsson L (August 1994). "Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service". Therapeutic Drug Monitoring. 16 (4): 368–374.
doi:
10.1097/00007691-199408000-00006.
PMID7974626.
S2CID31325882.
^Raaska K, Neuvonen PJ (November 2000). "Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia". European Journal of Clinical Pharmacology. 56 (8): 585–589.
doi:
10.1007/s002280000192.
PMID11151749.
S2CID20390680.
^Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2014.
^
abRoth BL, Driscol J.
"PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
^
abRoth BL, Driscol J.
"PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
^"Clozapine | C18H19ClN4". PubChem. U.S. Library of Medicine.
Archived from the original on 24 December 2013. Retrieved 16 July 2017.
^Wu Y, Blichowski M, Daskalakis ZJ, Wu Z, Liu CC, Cortez MA, et al. (September 2011). "Evidence that clozapine directly interacts on the GABAB receptor". NeuroReport. 22 (13): 637–641.
doi:
10.1097/WNR.0b013e328349739b.
PMID21753741.
S2CID277293.
^Vacher CM, Gassmann M, Desrayaud S, Challet E, Bradaia A, Hoyer D, et al. (May 2006). "Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice". Journal of Neurochemistry. 97 (4): 979–991.
doi:
10.1111/j.1471-4159.2006.03806.x.
PMID16606363.
S2CID19780444.
^Disanto AR, Golden G (1 August 2009). "Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects". Clinical Drug Investigation. 29 (8): 539–549.
doi:
10.2165/00044011-200929080-00004.
PMID19591515.
S2CID45731786.
^
abRostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (February 2004). "Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients". Journal of Clinical Psychopharmacology. 24 (1): 70–78.
doi:
10.1097/01.jcp.0000106221.36344.4d.
PMID14709950.
S2CID31923731.
^Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW (January 1999). "Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics". The Journal of Clinical Psychiatry. 60 (1): 36–40.
doi:
10.4088/JCP.v60n0108.
PMID10074876.
^Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR (2001). "Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis". The Canadian Journal of Clinical Pharmacology. 8 (4): 199–206.
PMID11743592.
"Clozapine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2 October 2018. Retrieved 12 February 2023.{{
cite web}}: CS1 maint: bot: original URL status unknown (
link)